Results 81 to 90 of about 224,676 (168)

Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.

, 2020
PURPOSE: Patients with Graves' orbitopathy can present with asymmetric disease. The aim of this study was to identify clinical characteristics that distinguish asymmetric from unilateral and symmetric Graves' orbitopathy. METHODS: This was a multi-centre
Boschi, Antonella, Pitz, Susanne, Dayan, Colin M, Menconi, Francesca, Morris, Daniel S, Pearce, Simon H, Hegedüs, László, Leo, Marenza, Clarke, Lucy, Muller, Ilaria, Mathiopoulou, Lemonia, Currò, Nicola, Marcocci, Claudio, Azzolini, Claudio, Brix, Thomas H, Nardi, Marco, Bernard, Martine, Ẑarković, Miloš P, Daumerie, Chantal, Fichter, Nicole, European Group on Graves’ Orbitopathy, Covelli, Danila, Ćirić, Slavica, Salvi, Mario, Möller, Lars, Panagiotou, Grigorios C, Törüner, Füsun, Perros, Petros, Ayvaz, Göksun, Baldeschi, Lelio, Bartalena, Luigi, Knežević, Miroslav, Konuk, Onur, Orgiazzi, Jacques, Marinò, Michele, Kahaly, Georges J, Okosieme, Onyebuchi E, Lareida, Jürg J, Eckstein, Anja K, Wiersinga, Wilmar M   +39 more
core   +1 more source

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy

Archives of Endocrinology and Metabolism
Objective Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the
Mira Siderova, Kiril Hristozov, Aleksandra Tsukeva   +2 more
doaj   +1 more source

Statin reduces orbitopathy risk in patients with Graves’ disease by modulating apoptosis and autophagy activities

, 2016
Statins use has been associated with reduced risk for developing orbitopathy among patients with Graves’ disease. We hypothesize that statin reduces orbitopathy risk mainly by modulating both apoptosis and autophagy activities in patients with Graves ...
Ciaglia Elena, CIAGLIA, ELENA, Bifulco Maurizio, BIFULCO, Maurizio   +3 more
core   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Graves’ orbitopathy: the importance of statin therapy [PDF]

Background. Graves’ orbitopathy is the most common extrathyroidal autoimmune disorder, predominantly caused by hyperthyroidism. Prevention and development of an individualized treatment plan involve the use of statins and the management of risk factors:
Rizov, Cristina, Tidvă, Adelina
core  

Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?

Clinical Case Reports, 2018
Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell
Luminita Nicoleta Cima, Ioana Maria Lambrescu, Lavinia Stejereanu, Anca Colita, Reuven Or, Simona Fica   +5 more
doaj   +1 more source

Diagnostic Approaches to and Disaese Course Modifying Therapies in Graves Orbitopathy

Graves' Orbitopathy (GO) is an autoimmune condition that primarily affects the orbit, causing inflammation, muscle expansion, and tissue changes. Although often linked to Graves' Disease (GD), 5-10% of GO patients may not have GD at diagnosis.
Muthomi, Brenda Shey Wanjira
core  

Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures.

, 2009
Aim: To compare the outcome of various surgical approaches of orbital decompression in patients with Graves' orbitopathy (GO) receiving surgery for disfiguring proptosis.
MARINO', MICHELE, Currò N, Freidel M, Bijl H, PINCHERA, ALDO, Salvi M, Mourits MP, Mohr Ch, Neoh C, Nardi M, Pinchera A, Kahaly GJ, Sellari Franceschini S, Pitz S, Altea MA, NARDI, MARCO, Guastella C, Orgiazzi J, European Group on Graves' Orbitopathy, von Arx G, Marcocci C, MARCOCCI, CLAUDIO, Boboridis K, Wiersinga WM, Eckstein A, Lane CM, Wiersinga W.M., Stahl M, BALDESCHI, LELIO, Saeed P, SELLARI FRANCESCHINI, STEFANO, Lareida J, Kalmann R, Krassas GE, Curr? N, Dickinson AJ   +35 more
core   +1 more source

What\u27s New in Graves\u27 Orbitopathy?

, 2018
Graves\u27 orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves\u27 disease (GD). Depending upon the diagnostic criteria used up to 50% of patients with GD have ophthalmic findings; with lid retraction/lid lag being the most ...
Jim Garrity, MD
core   +1 more source

Targeted immunotherapies for Graves’ thyroidal & orbital diseases

Frontiers in Immunology
BackgroundGraves’ hyperthyroidism and its associated Graves’ orbitopathy are common autoimmune disorders associated with significant adverse health impact.
Alan Chun Hong Lee, George J. Kahaly
doaj   +1 more source